Cancers | Highly Viewed Papers and Hot Topic Special Issues Published in the “Cancer Therapy” Section

We are delighted to share a collection of highly viewed papers in the “Cancer Therapy” Section that were published in Cancers (ISSN: 2072-6694) in the first half of 2025. In addition, some Special Issues on this topic are currently open for submission. The following is a list of articles and Special Issues that we believe may be of interest to you:

The list of relevant papers can be seen below:

“Recent Anti-KRAS^G12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma”
by Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo and Giovanni Marchegiani
Cancers 2025, 17(4), 704; https://doi.org/10.3390/cancers17040704
Available online: https://www.mdpi.com/2072-6694/17/4/704

“Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies”
by Valencia Mc Neil and Seung Won Lee
Cancers 2025, 17(9), 1408; https://doi.org/10.3390/cancers17091408
Available online: https://www.mdpi.com/2072-6694/17/9/1408

“Ancestry-Specific DNA Damage Repair Gene Mutations and Prostate Cancer”
by Talaibek Borbiev, Kevin Babcock, Kayleigh Sinopole, Gregory T. Chesnut and Gyorgy Petrovics
Cancers 2025, 17(4), 682; https://doi.org/10.3390/cancers17040682
Available online: https://www.mdpi.com/2072-6694/17/4/682

“Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial–Mesenchymal Transition”
by Ewa Błaszczak, Paulina Miziak, Adrian Odrzywolski, Marzena Baran, Ewelina Gumbarewicz and Andrzej Stepulak
Cancers 2025, 17(2), 228; https://doi.org/10.3390/cancers17020228
Available online: https://www.mdpi.com/2072-6694/17/2/228

“Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics”
by Yan-You Liao, Chia-Luen Tsai and Hsiang-Po Huang
Cancers 2025, 17(3), 459; https://doi.org/10.3390/cancers17030459
Available online: https://www.mdpi.com/2072-6694/17/3/459

“Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies”
by Ayrton Bangolo, Behzad Amoozgar, Charlene Mansour, Lili Zhang, Sarvarinder Gill, Andrew Ip and Christina Cho
Cancers 2025, 17(2), 282; https://doi.org/10.3390/cancers17020282
Available online: https://www.mdpi.com/2072-6694/17/2/282

Special Issues:

You can view and submit relevant papers to Cancers via the following link: https://www.mdpi.com/journal/cancers.

Cancers Editorial Office